Download PDF
Semin Respir Crit Care Med 2016; 37(05): 760-770
DOI: 10.1055/s-0036-1592337
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer

Manish K. Thakur
1   Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
,
Shirish M. Gadgeel
1   Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

    Permissions and Reprints

Abstract

Therapy of non-small cell lung cancer (NSCLC) patients has evolved over the past few years with the incorporation of targeted therapy and immune therapy. These changes have increased the importance of prognostic and predictive biomarkers to enable practicing physicians in making the most appropriate treatment decisions for NSCLC patients. A variety of prognostic factors based on clinical and pathologic features determine the overall outcome of the patient and these factors do influence decisions regarding initiation of therapy. The most important prognostic factors remain stage of the disease at diagnosis and performance status. For years, the only approved systemic therapy for NSCLC patients was chemotherapy. Despite attempts at defining factors that influence efficacy of chemotherapeutic agents, pemetrexed is the only chemotherapy drug that has differential activity based on a specific factor. In recent years, there is increasing focus on defining the molecular alterations critical to the oncogenic phenotype of NSCLC and targeting these alterations for therapeutic benefit. In addition, there is increasing use of immune-modulating drugs, specifically anti-PD-1 drugs, in advanced NSCLC patients. Several studies have shown that the probability of clinical benefit from these agents is greater in patients with NSCLCs that express PD-L1. The totality of these data suggests that determination of predictive markers prior to initiation of therapy is critical.

Keywords

NSCLC - prognostic - predictive - biomarkers - targeted therapy - immune therapy
 

  • References

  • 1 Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P ; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4 (7) 792-801
    CrossrefPubMedGoogle Scholar
  • 2 Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology 2011; 16 (8) 1210-1220
    CrossrefPubMedGoogle Scholar
  • 3 Scagliotti GV, Parikh P, von Pawel J , et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
    CrossrefPubMedGoogle Scholar
  • 4 Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66 (3) 431-438
    CrossrefPubMedGoogle Scholar
  • 5 Takezawa K, Okamoto I, Okamoto W , et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011; 104 (10) 1594-1601
    CrossrefPubMedGoogle Scholar
  • 6 Ardizzoni A, Boni L, Tiseo M , et al; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99 (11) 847-857
    CrossrefPubMedGoogle Scholar
  • 7 Sandler A, Gray R, Perry MC , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24) 2542-2550
    CrossrefPubMedGoogle Scholar
  • 8 Johnson DH, Fehrenbacher L, Novotny WF , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
    CrossrefPubMedGoogle Scholar
  • 9 Cagini L, Monacelli M, Giustozzi G , et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000; 74 (1) 53-60
    CrossrefPubMedGoogle Scholar
  • 10 Shimada Y, Saji H, Kato Y , et al. The frequency and prognostic impact of pathological microscopic vascular invasion according to tumor size in non-small cell lung cancer. Chest 2016; 149 (3) 775-785
    CrossrefPubMedGoogle Scholar
  • 11 Schuchert MJ, Schumacher L, Kilic A , et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg 2011; 91 (4) 1059-1065 , discussion 1065
    CrossrefPubMedGoogle Scholar
  • 12 Kudo Y, Saji H, Shimada Y , et al. Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer. Lung Cancer 2012; 78 (2) 153-160
    CrossrefPubMedGoogle Scholar
  • 13 Fibla JJ, Cassivi SD, Brunelli A , et al. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set. Lung Cancer 2012; 78 (3) 259-262
    CrossrefPubMedGoogle Scholar
  • 14 Rusch VW, Hawes D, Decker PA , et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011; 29 (32) 4313-4319
    CrossrefPubMedGoogle Scholar
  • 15 Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105 (1) 93-103
    CrossrefPubMedGoogle Scholar
  • 16 Bremnes RM, Busund LT, Kilvær TL , et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol 2016; 11 (6) 789-800
    CrossrefPubMedGoogle Scholar
  • 17 Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14 (6) 959-970
    PubMedGoogle Scholar
  • 18 Olaussen KA, Dunant A, Fouret P , et al; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355 (10) 983-991
    CrossrefPubMedGoogle Scholar
  • 19 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J ; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350 (4) 351-360
    CrossrefPubMedGoogle Scholar
  • 20 Choi CM, Yang SC, Jo HJ , et al. Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol 2012; 23 (8) 2088-2093
    CrossrefPubMedGoogle Scholar
  • 21 Lord RV, Brabender J, Gandara D , et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8 (7) 2286-2291
    PubMedGoogle Scholar
  • 22 Bepler G, Williams C, Schell MJ , et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013; 31 (19) 2404-2412
    CrossrefPubMedGoogle Scholar
  • 23 Friboulet L, Olaussen KA, Pignon JP , et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368 (12) 1101-1110
    CrossrefPubMedGoogle Scholar
  • 24 Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003; 22 (14) 2135-2142
    CrossrefPubMedGoogle Scholar
  • 25 Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356 (8) 800-808
    CrossrefPubMedGoogle Scholar
  • 26 Bergman AM, Eijk PP, Ruiz van Haperen VW , et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65 (20) 9510-9516
    CrossrefPubMedGoogle Scholar
  • 27 Rosell R, Danenberg KD, Alberola V , et al; Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10 (4) 1318-1325
    CrossrefPubMedGoogle Scholar
  • 28 Bepler G, Kusmartseva I, Sharma S , et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24 (29) 4731-4737
    CrossrefPubMedGoogle Scholar
  • 29 Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005; 50 (2) 211-219
    CrossrefPubMedGoogle Scholar
  • 30 Rosell R, Skrzypski M, Jassem E , et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007; 2 (11) e1129
    CrossrefPubMedGoogle Scholar
  • 31 Wang L, Wei J, Qian X , et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008; 8: 97
    CrossrefPubMedGoogle Scholar
  • 32 Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20 (45) 6597-6606
    CrossrefPubMedGoogle Scholar
  • 33 Aggarwal C, Somaiah N, Simon GR. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. J Natl Compr Canc Netw 2010; 8 (7) 822-832
    PubMedGoogle Scholar
  • 34 Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. . J Exp Clin Cancer Res 2013; 32: 15
    CrossrefPubMedGoogle Scholar
  • 35 Moran T, Wei J, Cobo M , et al; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol 2014; 25 (11) 2147-2155
    CrossrefPubMedGoogle Scholar
  • 36 Monzó M, Rosell R, Sánchez JJ , et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17 (6) 1786-1793
    CrossrefPubMedGoogle Scholar
  • 37 Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008; 9 (2) 168-175
    CrossrefPubMedGoogle Scholar
  • 38 Reiman T, Lai R, Veillard AS , et al; LACE-Bio Group. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012; 23 (1) 86-93
    CrossrefPubMedGoogle Scholar
  • 39 Burstein HJ, Mangu PB, Somerfield MR , et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 2011; 29 (24) 3328-3330
    CrossrefPubMedGoogle Scholar
  • 40 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10 (11) 760-774
    CrossrefPubMedGoogle Scholar
  • 41 Kuan FC, Kuo LT, Chen MC , et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 2015; 113 (10) 1519-1528
    CrossrefPubMedGoogle Scholar
  • 42 Balak MN, Gong Y, Riely GJ , et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12 (21) 6494-6501
    CrossrefPubMedGoogle Scholar
  • 43 Godin-Heymann N, Ulkus L, Brannigan BW , et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008; 7 (4) 874-879
    CrossrefPubMedGoogle Scholar
  • 44 Jänne PA, Yang JC, Kim DW , et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372 (18) 1689-1699
    CrossrefPubMedGoogle Scholar
  • 45 D'Angelo SP, Janjigian YY, Ahye N , et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7 (12) 1815-1822
    CrossrefPubMedGoogle Scholar
  • 46 Goss GD, O'Callaghan C, Lorimer I , et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013; 31 (27) 3320-3326
    CrossrefPubMedGoogle Scholar
  • 47 Kelly K, Altorki NK, Eberhardt WE , et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 2015; 33 (34) 4007-4014
    CrossrefPubMedGoogle Scholar
  • 48 Kris MG, Johnson BE, Berry LD , et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311 (19) 1998-2006
    CrossrefPubMedGoogle Scholar
  • 49 Doebele RC, Camidge DR. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012; 7 (16) (Suppl. 05) S375-S376
    CrossrefPubMedGoogle Scholar
  • 50 Shaw AT, Kim DW, Nakagawa K , et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedGoogle Scholar
  • 51 Solomon BJ, Mok T, Kim DW , et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 52 Choi YL, Soda M, Yamashita Y , et al; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363 (18) 1734-1739
    CrossrefPubMedGoogle Scholar
  • 53 Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014; 351 (2) 215-221
    CrossrefPubMedGoogle Scholar
  • 54 Toyokawa G, Hirai F, Inamasu E , et al. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol 2014; 9 (12) e86-e87
    CrossrefPubMedGoogle Scholar
  • 55 Doebele RC, Pilling AB, Aisner DL , et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18 (5) 1472-1482
    CrossrefPubMedGoogle Scholar
  • 56 Katayama R, Shaw AT, Khan TM , et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4 (120) 120ra17
    CrossrefPubMedGoogle Scholar
  • 57 Ou SH, Ahn JS, De Petris L , et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34 (7) 661-668
    CrossrefPubMedGoogle Scholar
  • 58 Camidge DR, Kono SA, Lu X , et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011; 6 (4) 774-780
    CrossrefPubMedGoogle Scholar
  • 59 Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013; 31 (8) 1112-1121
    CrossrefPubMedGoogle Scholar
  • 60 Mascaux C, Iannino N, Martin B , et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92 (1) 131-139
    CrossrefPubMedGoogle Scholar
  • 61 Shepherd FA, Domerg C, Hainaut P , et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31 (17) 2173-2181
    CrossrefPubMedGoogle Scholar
  • 62 Johnson ML, Sima CS, Chaft J , et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013; 119 (2) 356-362
    CrossrefPubMedGoogle Scholar
  • 63 Brugger W, Triller N, Blasinska-Morawiec M , et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29 (31) 4113-4120
    CrossrefPubMedGoogle Scholar
  • 64 Jänne PA, Shaw AT, Pereira JR , et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14 (1) 38-47
    CrossrefPubMedGoogle Scholar
  • 65 Chen Z, Cheng K, Walton Z , et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483 (7391) 613-617
    CrossrefPubMedGoogle Scholar
  • 66 Bergethon K, Shaw AT, Ou SH , et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30 (8) 863-870
    CrossrefPubMedGoogle Scholar
  • 67 Shaw AT, Ou SH, Bang YJ , et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371 (21) 1963-1971
    CrossrefPubMedGoogle Scholar
  • 68 Hyman DM, Puzanov I, Subbiah V , et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373 (8) 726-736
    CrossrefPubMedGoogle Scholar
  • 69 Planchard D, Besse B, Groen HJ , et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016; 17 (7) 984-993
    CrossrefPubMedGoogle Scholar
  • 70 Camidge DR, Ou S-HI, Shapiro G , et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014 32:8001
    PubMedGoogle Scholar
  • 71 Paik PK, Drilon A, Fan PD , et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015; 5 (8) 842-849
    CrossrefPubMedGoogle Scholar
  • 72 Drilon AE, Sima CS, Somwar R , et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. ASCO Meeting Abstracts 2015 33:8007
    PubMedGoogle Scholar
  • 73 Mazières J, Peters S, Lepage B , et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31 (16) 1997-2003
    CrossrefPubMedGoogle Scholar
  • 74 Weeden CE, Solomon B, Asselin-Labat ML. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Dis 2015; 1: 15049
    CrossrefPubMedGoogle Scholar
  • 75 Chen HY, Yu SL, Chen CH , et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 76 Zhu CQ, Ding K, Strumpf D , et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28 (29) 4417-4424
    CrossrefPubMedGoogle Scholar
  • 77 Kratz JR, He J, Van Den Eeden SK , et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379 (9818) 823-832
    CrossrefPubMedGoogle Scholar
  • 78 Tan X, Qin W, Zhang L , et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011; 17 (21) 6802-6811
    CrossrefPubMedGoogle Scholar
  • 79 Tian L, Shan W, Zhang Y, Lv X, Li X, Wei C. Up-regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer. Pathol Oncol Res 2016; 22 (1) 161-167
    CrossrefPubMedGoogle Scholar
  • 80 Johnson SM, Grosshans H, Shingara J , et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120 (5) 635-647
    Google Scholar
  • 81 Dai X, Jiang Y, Tan C. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy. PLoS ONE 2015; 10 (5) e0126653
    CrossrefPubMedGoogle Scholar
  • 82 Naidu S, Garofalo M. microRNAs: an emerging paradigm in lung cancer chemoresistance. Front Med (Lausanne) 2015; 2: 77
    PubMedGoogle Scholar
  • 83 Dong Z, Zhong Z, Yang L, Wang S, Gong Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 2014; 343 (2) 249-257
    CrossrefPubMedGoogle Scholar
  • 84 Shen H, Zhu F, Liu J , et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS ONE 2014; 9 (7) e103305
    CrossrefPubMedGoogle Scholar
  • 85 Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol 2016; 11 (7) 976-988
    CrossrefPubMedGoogle Scholar
  • 86 Brahmer J, Reckamp KL, Baas P , et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (2) 123-135
    CrossrefPubMedGoogle Scholar
  • 87 Borghaei H, Paz-Ares L, Horn L , et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373 (17) 1627-1639
    CrossrefPubMedGoogle Scholar
  • 88 Garon EB, Rizvi NA, Hui R , et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21) 2018-2028
    CrossrefPubMedGoogle Scholar
  • 89 Herbst RS, Baas P, Kim DW , et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027) 1540-1550
    CrossrefPubMedGoogle Scholar
  • 90 Fehrenbacher L, Spira A, Ballinger M , et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387 (10030) 1837-1846
    CrossrefPubMedGoogle Scholar
  • 91 Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348 (6230) 124-128
    CrossrefPubMedGoogle Scholar
  • 92 Taguchi F, Solomon B, Gregorc V , et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99 (11) 838-846
    CrossrefPubMedGoogle Scholar
  • 93 Carbone DP, Ding K, Roder H , et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 2012; 7 (11) 1653-1660
    CrossrefPubMedGoogle Scholar
  • 94 Gregorc V, Novello S, Lazzari C , et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014; 15 (7) 713-721
    CrossrefPubMedGoogle Scholar
  • 95 Diaz Jr LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32 (6) 579-586
    CrossrefPubMedGoogle Scholar
  • 96 Wu YL, Zhou C, Liam CK , et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26 (9) 1883-1889
    CrossrefPubMedGoogle Scholar
  • 97 Zheng D, Ye X, Zhang MZ , et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 2016; 6: 20913
    CrossrefPubMedGoogle Scholar
  • 98 Zill OA, Mortimer S, Banks KC , et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. ASCO Meeting Abstracts 2016 34:LBA11501
    PubMedGoogle Scholar
  • 99 Francis G, Stein S. Circulating cell-free tumour DNA in the management of cancer. Int J Mol Sci 2015; 16 (6) 14122-14142
    CrossrefPubMedGoogle Scholar